Abstract
Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance development is not a valid argument to refrain from temporary early treatment during PHI.
Original language | Undefined/Unknown |
---|---|
Journal | PLoS One (print) |
Volume | 9 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2014 |
Externally published | Yes |
Research programs
- EMC MM-04-28-04